Emily Pauline Rabinovich
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Emily Pauline Rabinovich has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Allan Tsung
Department of Surgery, University of Virginia, Charlottesville, Virginia, USA
10 shared publications - Carolyn Tsung
Department of Surgery, University of Virginia, Charlottesville, Virginia
10 shared publications - Chengli Shen
Division of Surgical Sciences, Department of Surgery (R.T., Y.H., T.S., J.L., C.S., X.Z., J.M., K.C.K., L.-W.G.), School of Medicine, University of Virginia, Charlottesville
10 shared publications - David R. Brenin
Department of Surgery, University of Virginia, Charlottesville, Virginia
10 shared publications - Kaelyn C. Cummins
Department of Surgery University of Virginia Charlottesville Virginia USA
10 shared publications - Mohamad El Moheb
Department of Surgery University of Virginia Charlottesville Virginia USA
10 shared publications
Latest Publications
- Open Access
- 2 October 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (19) , 7644
Biomarker Integration in the Perioperative Management of Early-Stage Non-Small-Cell Lung Cancer
The concept of personalized medicine has tremendous appeal—tailoring diagnosis and treatment to an individual, rather than a “one-size-fits-all” approach. The management of non-small-cell lung cancer (NSCLC) has rapidly evolved toward strategies increasingly guided by tumor biology and precision oncology. The safety and significant efficacy of biomarker-directed therapies in metastatic disease have fueled interest in applying precision oncology to early-stage, operable NSCLC. Advances in molecular profiling have revealed that a substantial proportion of resected NSCLC harbor actionable driver mutations, enabling the integration of targeted therapies into the perioperative setting. The success of adjuvant epidermal growth factor receptor and anaplastic lymphoma kinase inhibition established a framework for biomarker-driven therapy and highlights the importance of comprehensive molecular testing at diagnosis. In parallel, perioperative immune checkpoint inhibitor-based strategies have expanded treatment options for appropriately selected patients, further emphasizing the importance of molecular profiling. Significant implementation gaps remain, including incomplete molecular testing, delayed results, inadequate tissue sampling, fragmented workflows, and disparities in access. Beyond clinically actionable driver mutations, emerging research highlights radiogenomics and advances in the use of circulating tumor DNA for minimal residual disease detection, with important implications for early recurrence detection and patient prognostication, although these technologies differ in clinical maturity. Collectively, these developments emphasize the molecular heterogeneity underlying early-stage NSCLC and the expanding role of biomarkers in guiding clinical decision-making. Integrating genomic, radiographic, and biologic markers into clinical workflows will be essential to refine risk stratification, personalize perioperative treatment strategies, and ultimately improve long-term oncologic outcomes.
- 2 October 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (19) , 7644
Open AccessBiomarker Integration in the Perioperative Management of Early-Stage Non-Small-Cell Lung Cancer
The concept of personalized medicine has tremendous appeal—tailoring diagnosis and treatment to an individual, rather than a “one-size-fits-all” approach. The management of non-small-cell lung cancer (NSCLC) has rapidly evolved toward strategies increasingly guided by tumor biology and precision oncology. The safety and significant efficacy of biomarker-directed therapies in metastatic disease have fueled interest in applying precision oncology to early-stage, operable NSCLC. Advances in molecular profiling have revealed that a substantial proportion of resected NSCLC harbor actionable driver mutations, enabling the integration of targeted therapies into the perioperative setting. The success of adjuvant epidermal growth factor receptor and anaplastic lymphoma kinase inhibition established a framework for biomarker-driven therapy and highlights the importance of comprehensive molecular testing at diagnosis. In parallel, perioperative immune checkpoint inhibitor-based strategies have expanded treatment options for appropriately selected patients, further emphasizing the importance of molecular profiling. Significant implementation gaps remain, including incomplete molecular testing, delayed results, inadequate tissue sampling, fragmented workflows, and disparities in access. Beyond clinically actionable driver mutations, emerging research highlights radiogenomics and advances in the use of circulating tumor DNA for minimal residual disease detection, with important implications for early recurrence detection and patient prognostication, although these technologies differ in clinical maturity. Collectively, these developments emphasize the molecular heterogeneity underlying early-stage NSCLC and the expanding role of biomarkers in guiding clinical decision-making. Integrating genomic, radiographic, and biologic markers into clinical workflows will be essential to refine risk stratification, personalize perioperative treatment strategies, and ultimately improve long-term oncologic outcomes.
- Open Access
- 10 June 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (12) , 4493
Precision at the Margin: Innovations and Challenges in Intraoperative Molecular Imaging for Thoracic Surgery
Tumor localization during pulmonary surgery has become increasingly challenging with the earlier detection of smaller and smaller lung nodules. Concomitantly, minimally invasive surgical (MIS) techniques have been increasingly adopted within the field of thoracic surgical oncology. Surgeons face growing challenges not only with locating these small tumors, but also with immediate margin assessment, reduced tactile feedback, and nodal assessment. Intraoperative molecular imaging (IMI) has emerged as a promising adjunct to address these challenges by enabling real-time visualization of malignant tissue during pulmonary resection. In its current form, IMI integrates systemically administered, tumor-targeting near-infrared fluorophores with fluorescence-capable imaging platforms to enhance intraoperative decision-making. Early clinical experiences in thoracic surgery suggest particular utility in the localization of small or nonpalpable pulmonary nodules and for improved margin assessment during MIS. Despite encouraging preliminary data, widespread adoption of IMI remains limited by biologic variability in target expression, optical depth constraints, false-positive fluorescence in inflammatory tissue, and challenges in workflow integration. Applications for nodal evaluation, staging, and longer-term oncologic outcome improvement remain investigational. Addressing these multifaceted barriers will be essential for the translation of IMI from a promising, experimental adjunct to a more broadly implementable surgical technology. This work summarizes the current state of IMI in thoracic surgical oncology, highlighting key translational studies, established and emerging clinical applications, and critical limitations within the current landscape. The authors also outline future directions for the field, including quantitative fluorescence interpretation, standardized reporting, and outcomes-driven clinical trials evaluating margin adequacy, recurrence, staging impact, and cost-effectiveness to support widespread evidence-based implementation.
- 10 June 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (12) , 4493
Open AccessPrecision at the Margin: Innovations and Challenges in Intraoperative Molecular Imaging for Thoracic Surgery
Tumor localization during pulmonary surgery has become increasingly challenging with the earlier detection of smaller and smaller lung nodules. Concomitantly, minimally invasive surgical (MIS) techniques have been increasingly adopted within the field of thoracic surgical oncology. Surgeons face growing challenges not only with locating these small tumors, but also with immediate margin assessment, reduced tactile feedback, and nodal assessment. Intraoperative molecular imaging (IMI) has emerged as a promising adjunct to address these challenges by enabling real-time visualization of malignant tissue during pulmonary resection. In its current form, IMI integrates systemically administered, tumor-targeting near-infrared fluorophores with fluorescence-capable imaging platforms to enhance intraoperative decision-making. Early clinical experiences in thoracic surgery suggest particular utility in the localization of small or nonpalpable pulmonary nodules and for improved margin assessment during MIS. Despite encouraging preliminary data, widespread adoption of IMI remains limited by biologic variability in target expression, optical depth constraints, false-positive fluorescence in inflammatory tissue, and challenges in workflow integration. Applications for nodal evaluation, staging, and longer-term oncologic outcome improvement remain investigational. Addressing these multifaceted barriers will be essential for the translation of IMI from a promising, experimental adjunct to a more broadly implementable surgical technology. This work summarizes the current state of IMI in thoracic surgical oncology, highlighting key translational studies, established and emerging clinical applications, and critical limitations within the current landscape. The authors also outline future directions for the field, including quantitative fluorescence interpretation, standardized reporting, and outcomes-driven clinical trials evaluating margin adequacy, recurrence, staging impact, and cost-effectiveness to support widespread evidence-based implementation.
- Open Access
- 2 June 2026
- Published by Elsevier in JTCVS Open
- Vol. 32
Sodium bicarbonate attenuates myocardial ischemia-reperfusion injury via activation of the splenic cholinergic anti-inflammatory pathway
- 2 June 2026
- Published by Elsevier in JTCVS Open
- Vol. 32
Open AccessSodium bicarbonate attenuates myocardial ischemia-reperfusion injury via activation of the splenic cholinergic anti-inflammatory pathway
- Open Access
- 9 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Predicting Health-Related Quality of Life Trajectories in Elderly Patients with Breast Cancer: From Prediagnosis to Long-term Follow-up
Supplementary Figure 2 shows posterior predictive checks for the model predicting PCS change from diagnosis to two years. The three panels compare observed versus replicated data in terms of overall distribution, mean, and variance to assess model fit.
- 9 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Predicting Health-Related Quality of Life Trajectories in Elderly Patients with Breast Cancer: From Prediagnosis to Long-term Follow-up
Supplementary Figure 2 shows posterior predictive checks for the model predicting PCS change from diagnosis to two years. The three panels compare observed versus replicated data in terms of overall distribution, mean, and variance to assess model fit.
- Open Access
- 9 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Predicting Health-Related Quality of Life Trajectories in Elderly Patients with Breast Cancer: From Prediagnosis to Long-term Follow-up
Supplementary Figure 1 shows violin plots with medians and interquartile ranges for baseline physical (PCS) and mental (MCS) component scores, before versus after diagnosis (Panel A), and at diagnosis versus two years later (Panel B).
- 9 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Predicting Health-Related Quality of Life Trajectories in Elderly Patients with Breast Cancer: From Prediagnosis to Long-term Follow-up
Supplementary Figure 1 shows violin plots with medians and interquartile ranges for baseline physical (PCS) and mental (MCS) component scores, before versus after diagnosis (Panel A), and at diagnosis versus two years later (Panel B).
- Open Access
- 9 January 2026
- Published by American Association for Cancer Research (AACR)
Data from Predicting Health-Related Quality of Life Trajectories in Elderly Patients with Breast Cancer: From Prediagnosis to Long-term Follow-up
Background:Evidence comparing patients’ health-related quality of life (HRQOL) before and after breast cancer diagnosis, and factors influencing these trajectories, is limited because of unpredictable onset. We analyzed predictors of HRQOL change in elderly patients with breast cancer across two transitions: pre- to post-diagnosis and at diagnosis versus 2 years later.Methods:Using Surveillance, Epidemiology, and End Results–Medicare Health Outcomes Survey linkage, we analyzed patients with breast cancer >65 years who completed two HRQOL surveys. Two cohorts were examined: patients with surveys before and within 1 year after diagnosis (cohort 1) and those with surveys within 1 year of diagnosis and 2 years after diagnosis (cohort 2). Bayesian regression identified predictors of physical component summary (PCS) and mental component summary (MCS) score changes.Results:In cohort 1 (n = 1,546), advanced stage was associated with greater HRQOL decline, with mean PCS changes ranging from −2.1 to −6.5 and MCS from −2.0 to −5.1. Baseline activities of daily living (ADL) limitations were associated with mean PCS declines ranging from −2.0 to −2.6 and mean MCS decline of −2.0. Better baseline health perception was protective with mean PCS increases ranging from +1.4 to +3.4. In cohort 2 (n = 891), baseline ADL limitations were associated with mean PCS declines ranging from −1.6 to −5.5 and mean MCS decline of −2.5, whereas poor health perception was associated with mean PCS decline of −3.2. Excellent health perception was protective (mean MCS: +4.1). Surgery, chemotherapy, and radiation had no HRQOL affect.Conclusions:Baseline health perception and ADL limitations are critical determinants of HRQOL trajectories, outweighing treatments.Impact:Early intervention strategies based on baseline assessments may improve survivorship.
- 9 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Predicting Health-Related Quality of Life Trajectories in Elderly Patients with Breast Cancer: From Prediagnosis to Long-term Follow-up
Background:Evidence comparing patients’ health-related quality of life (HRQOL) before and after breast cancer diagnosis, and factors influencing these trajectories, is limited because of unpredictable onset. We analyzed predictors of HRQOL change in elderly patients with breast cancer across two transitions: pre- to post-diagnosis and at diagnosis versus 2 years later.Methods:Using Surveillance, Epidemiology, and End Results–Medicare Health Outcomes Survey linkage, we analyzed patients with breast cancer >65 years who completed two HRQOL surveys. Two cohorts were examined: patients with surveys before and within 1 year after diagnosis (cohort 1) and those with surveys within 1 year of diagnosis and 2 years after diagnosis (cohort 2). Bayesian regression identified predictors of physical component summary (PCS) and mental component summary (MCS) score changes.Results:In cohort 1 (n = 1,546), advanced stage was associated with greater HRQOL decline, with mean PCS changes ranging from −2.1 to −6.5 and MCS from −2.0 to −5.1. Baseline activities of daily living (ADL) limitations were associated with mean PCS declines ranging from −2.0 to −2.6 and mean MCS decline of −2.0. Better baseline health perception was protective with mean PCS increases ranging from +1.4 to +3.4. In cohort 2 (n = 891), baseline ADL limitations were associated with mean PCS declines ranging from −1.6 to −5.5 and mean MCS decline of −2.5, whereas poor health perception was associated with mean PCS decline of −3.2. Excellent health perception was protective (mean MCS: +4.1). Surgery, chemotherapy, and radiation had no HRQOL affect.Conclusions:Baseline health perception and ADL limitations are critical determinants of HRQOL trajectories, outweighing treatments.Impact:Early intervention strategies based on baseline assessments may improve survivorship.
- Open Access
- 9 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Predicting Health-Related Quality of Life Trajectories in Elderly Patients with Breast Cancer: From Prediagnosis to Long-term Follow-up
Supplementary Table S2 presents the posterior estimates, 95% credible intervals, and probabilities of direction (PD) for each predictor in the Bayesian regression model evaluating the association between patient factors and changes in Mental Component Summary (MCS) scores between pre-diagnosis and diagnosis relative to the minimally clinically important difference (MCID) threshold.
- 9 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Predicting Health-Related Quality of Life Trajectories in Elderly Patients with Breast Cancer: From Prediagnosis to Long-term Follow-up
Supplementary Table S2 presents the posterior estimates, 95% credible intervals, and probabilities of direction (PD) for each predictor in the Bayesian regression model evaluating the association between patient factors and changes in Mental Component Summary (MCS) scores between pre-diagnosis and diagnosis relative to the minimally clinically important difference (MCID) threshold.
- Open Access
- 9 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Predicting Health-Related Quality of Life Trajectories in Elderly Patients with Breast Cancer: From Prediagnosis to Long-term Follow-up
Supplementary Table S4 compares demographic, socioeconomic, clinical, and health-related baseline characteristics between two groups of elderly breast cancer patients from the SEER-MHOS dataset: those who completed both pre- and post-diagnosis HRQOL surveys (n=1,546) and those who completed only a pre-diagnosis survey (n=1,416). Differences are presented as proportions or mean differences with corresponding 95% confidence intervals. The table highlights potential selection biases in survey completion and the representativeness of the longitudinal cohort
- 9 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Predicting Health-Related Quality of Life Trajectories in Elderly Patients with Breast Cancer: From Prediagnosis to Long-term Follow-up
Supplementary Table S4 compares demographic, socioeconomic, clinical, and health-related baseline characteristics between two groups of elderly breast cancer patients from the SEER-MHOS dataset: those who completed both pre- and post-diagnosis HRQOL surveys (n=1,546) and those who completed only a pre-diagnosis survey (n=1,416). Differences are presented as proportions or mean differences with corresponding 95% confidence intervals. The table highlights potential selection biases in survey completion and the representativeness of the longitudinal cohort